Wednesday, October 16, 2019
News
NEWS HOME
»
PRESS RELEASES

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases
  SocialTwist Tell-a-Friend  
   


Date: 20-09-2019 6:02PM
Source: Boehringer Ingelheim
Category: General, Consumer Interest, Science & Research, Healthcare & Biotechnology, Pharmaceutical, Technology
Location: Ingelheim, Germany & Newton, Mass., United States

Business Wire India

  • Boehringer Ingelheim strengthens its retinal disease pipeline portfolio with new co-development and license agreement
  • The partners aim to develop novel therapies with significantly reduced patient burden for eye diseases with limited or only insufficient treatment options using Inflammasome Therapeutics’ intravitreal drug delivery technology
  • Inflammasome Therapeutics is entitled to receive up to $160 million in milestone and gated development payments as well as tiered royalties and other milestones due on commercialization

Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome’s unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelheim’s compounds from its retinal disease pipeline portfolio, Boehringer Ingelheim aims to develop novel therapies for retinal diseases.

In 2019 there were an estimated 82 million patients in the seven key countries (U.S., Japan, Germany, U.K., Spain, Italy, France) affected by one of the three major forms of retinal disease: Age related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic macular edema (DME). Globally, the prevalence rates of these and other retinal diseases are expected to increase over the next 10 years primarily due to aging populations and the global diabetes epidemic. Despite therapeutic advances in some disease areas during the past years, the real world results are poor, and there are no or only limited treatment options in many areas, resulting in an overall high unmet need. The collaboration between Boehringer Ingelheim and Inflammasome aims to address this challenge by using Inflammasome’s technology to deliver therapeutics in a biodegradable gel formulation into the eye.

“We are delighted to enter into a collaboration with a company of Boehringer Ingelheim’s stature,” said Paul Ashton, Chief Executive Officer of Inflammasome Therapeutics. “We look forward to working with their team to leverage our respective technologies and expertise to develop new therapies for devastating retinal diseases leading to blindness. This collaboration fits our strategy of advancing the company via both collaborations and internal development.”

“Boehringer Ingelheim is looking forward to developing Inflammasome’s novel technology for the delivery of our first-in- class retinal disease compounds working jointly with Inflammasome’s highly experienced scientific team,” said Clive R. Wood, PhD, Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim. “This will enable us to develop a broad range of novel therapy options for the many patients with retinal diseases waiting urgently for better and new therapy options.”

Boehringer Ingelheim takes a holistic approach in the development of novel retinal disease therapies, targeting key mechanisms in the pathogenesis of retinal diseases. The company has built a comprehensive pipeline portfolio of next generation therapy approaches in various stages of development up to Phase 2 in macular degeneration, diabetic retinal diseases and beyond. Inflammasome’s novel delivery technology using a long-acting degradable IVT implant complements this portfolio.

Inflammasome is entitled to receive up to $160 million in up-front, research and development support and milestone gated development payments as well as tiered royalties based on future commercial sales of developed products and other milestones due on commercialization.

Please click on the link for ´Notes to Editors´and ´References´:

http://www.boehringer-ingelheim.com/press-release/collaboration-novel-therapies-retinal-diseases



CONTACTS :

Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com

Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: + 203-791-6672
linda.ruckel@boehringer-ingelheim.com

Inflammasome Therapeutics
Bev. Jedynak
Bevlyn Consulting
+1 312 943 1123
+1 773 350 5793
blj@bevylnconsulting.com

More Press Releases

vivo Redefines the Offline Retail Experience for Customers: Launches First Ever Next-Gen Experience Zone in Chennai

PEI-Genesis Continues to Expand Global Reach With New Subsidiary in India: Sriram Nandakumar Named Field Application Engineer

Bajaj Finserv Announces Exciting Offers on #JustEMI to Make Your Diwali Sparkling

Boehringer Ingelheim Announces First Patient Enrolled in Phase II Trial of Novel Cystic Fibrosis Treatment (BALANCE-CFTM 1)

Gramener Named One of the Great Places to Work

Taulia Launches Next Generation Cash Forecasting Tool at EuroFinance Copenhagen 2019

Bank of America Reports Third-Quarter 2019 Financial Results

Dosti Realty Announces Dosti Lifelong Fiesta Offer for 2 of Its Residential Projects on the Auspicious Festive Occasion

How Rummy Passion Is Celebrating the Festival Month With All Rummy Players

Accomplishments of Dr. Steven Rosenberg in Cancer Immunotherapy Inspire Young Researchers in Japan & XIV Fujio Cup Quiz on Stem Cells Is Won by India.

Bertin Energy & Environment Looking for Green Energy Supply Solutions for the Giant SKA Radio Telescope

Future Gaming Announces Launch of Diwali Bumper Lotteries

Bajaj Finserv’s Sparkling Diwali: Avail Great Offers on Business Loans for Doctors

An ACE in the Hole: Boyd Corporation Enables Most Powerful GPU for Mobile Computing Devices

International Experts Invited to Attend Riyadh’s Sustainable City Symposium

ExaGrid Announces New Data Storage Solution for Acronis Cyber Backup

BCW Introduces BCW Eventus™, A Holistic Offering Serving Global Sporting Events

Andersen Global Enters Cameroon, Marking 18th Country in Africa

MSCI Schedules Investor Conference Call to Review Third Quarter 2019 Results

Mavenir Wins 2 Awards for Innovation at India Mobile Congress 2019

Dubai World Challenge for Self-Driving Transport Winners Announced for Prizes Worth USD 5.1 Million

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Unfortunate that Chidambaram has been pu...
INX Media case: 3 member ED team reaches...
PM Modi to hold 3 rallies in poll-bound ...
CCPA to meet for deciding on winter sess...
E-platform to ease up clearance of sanct...
BJP manages to put the political clock b...
More...    
 
 Top Stories
Non-local workforce makes a comebac... 
Right time to make investments: CEA... 
Gujarat artisans centre of attracti... 
Intel to acquire Smart Edge platfor... 
Mithali shuts down troll criticisin... 
Drama in SC, 'can't continue', CJI ... 
Heavier babies more likely to devel... 
Congress, NCP against national inte...